APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostacyclin

Prostaglandins are autocank derived from arachidonic acid. They both sustain homeostatic functions and mediate pathogenic mechanisms, including the inflammatory response. Prostaglandins control several processes in the body, especially as it relates to the healing process. When tissue is damaged or infected, this group of hormones will create the reactions that cause pain, fever and inflammation, which sparks the healing process. Prostaglandins also stimulate the formation of a blood clot and the contraction of the blood vessel wall when body is bleeding. Once blood clots are no longer needed and the injury begins to heal, another prostaglandin will stimulate the changes that allow the clots to dissipate and the blood vessel wall to relax.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Prostaglandins are autocank derived from arachidonic acid. They both sustain homeostatic functions and mediate pathogenic mechanisms, including the inflammatory response. Prostaglandins control several processes in the body, especially as it relates to the healing process. When tissue is damaged or infected, this group of hormones will create the reactions that cause pain, fever and inflammation, which sparks the healing process. Prostaglandins also stimulate the formation of a blood clot and the contraction of the blood vessel wall when body is bleeding. Once blood clots are no longer needed and the injury begins to heal, another prostaglandin will stimulate the changes that allow the clots to dissipate and the blood vessel wall to relax.

Selected research

Market Outlook & Growth Opportunities

Global Prostacyclin Market Outlook and Growth Opportunities 2026

26 December 2025194 pages

Choose your research edition.

Industry ResearchProstacyclin Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostacyclin Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Prostacyclin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostacyclin Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostacyclin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Prostaglandins are autocank derived from arachidonic acid. They both sustain homeostatic functions and mediate pathogenic mechanisms, including the inflammatory response. Prostaglandins control several processes in the body, especially as it relates to the healing process. When tissue is damaged or infected, this group of hormones will create the reactions that cause pain, fever and inflammation, which sparks the healing process. Prostaglandins also stimulate the formation of a blood clot and the contraction of the blood vessel wall when body is bleeding. Once blood clots are no longer needed and the injury begins to heal, another prostaglandin will stimulate the changes that allow the clots to dissipate and the blood vessel wall to relax.

United Therapeutics monopolizes the global Prostacyclin market, holding a share about 70%.

North America is the largest market, with a share about 80%, followed by Europe and Japan, have a share about 15 percent.

Read the full market overview

In terms of product, Beraprost Sodium is the largest segment, with a share over 50%. And in terms of application, the largest application is For Oral, followed by For Injection, For Inhalation.

This report provides an overview of the global Prostacyclin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prostacyclin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prostacyclin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prostacyclin market size, projected growth trends, production technologies, key applications, and end-use industries.

Prostacyclin Segment by Company

United Therapeutics

Actelion (J & J)

GSK

Teva

Toray

Tide Pharma

Bayer AG

Prostacyclin Segment by Type

Epoprostenol Sodium

Treprostinil

Iloprost

Beraprost Sodium

Prostacyclin Segment by Application

For Injection

For Oral

For Inhalation

Prostacyclin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Prostacyclin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Prostacyclin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Prostacyclin significant trends, drivers, influence factors in global and regions.

6. To analyze Prostacyclin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostacyclin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostacyclin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostacyclin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Prostacyclin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prostacyclin industry.

Chapter 3: Detailed analysis of Prostacyclin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Prostacyclin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Prostacyclin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Prostacyclin Industry Trends Table 2. Prostacyclin Industry Drivers Table 3. Prostacyclin Industry Opportunities and Challenges Table 4. Prostacyclin Industry Restraints Table 5. Global Prostacyclin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Prostacyclin Revenue Share by Company (2021-2026) Table 7. Global Prostacyclin Sales Volume by Company (K Unit) & (2021-2026) Table 8. Global Prostacyclin Sales Volume Share by Company (2021-2026) Table 9. Global Prostacyclin Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Prostacyclin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Prostacyclin Key Company Manufacturing Base & Headquarters Table 12. Global Prostacyclin Company, Product Type & Application Table 13. Global Prostacyclin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Prostacyclin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Epoprostenol Sodium Table 18. Significant Companies of Treprostinil Table 19. Significant Companies of Iloprost Table 20. Significant Companies of Beraprost Sodium Table 21. Global Prostacyclin Sales Volume by Type 2021 VS 2025 VS 2032 (K Unit) Table 22. Global Prostacyclin Sales Volume by Type (2021-2026) & (K Unit) Table 23. Global Prostacyclin Sales Volume by Type (2027-2032) & (K Unit) Table 24. Global Prostacyclin Sales Volume Share by Type (2021-2026) Table 25. Global Prostacyclin Sales Volume Share by Type (2027-2032) Table 26. Global Prostacyclin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Prostacyclin Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Prostacyclin Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Prostacyclin Sales Value Share by Type (2021-2026) Table 30. Global Prostacyclin Sales Value Share by Type (2027-2032) Table 31. Significant Companies of For Injection Table 32. Significant Companies of For Oral Table 33. Significant Companies of For Inhalation Table 34. Global Prostacyclin Sales Volume by Application 2021 VS 2025 VS 2032 (K Unit) Table 35. Global Prostacyclin Sales Volume by Application (2021-2026) & (K Unit) Table 36. Global Prostacyclin Sales Volume by Application (2027-2032) & (K Unit) Table 37. Global Prostacyclin Sales Volume Share by Application (2021-2026) Table 38. Global Prostacyclin Sales Volume Share by Application (2027-2032) Table 39. Global Prostacyclin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Prostacyclin Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Prostacyclin Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Prostacyclin Sales Value Share by Application (2021-2026) Table 43. Global Prostacyclin Sales Value Share by Application (2027-2032) Table 44. Global Prostacyclin Sales by Region: 2021 VS 2025 VS 2032 (K Unit) Table 45. Global Prostacyclin Sales by Region (2021-2026) & (K Unit) Table 46. Global Prostacyclin Sales Market Share by Region (2021-2026) Table 47. Global Prostacyclin Sales by Region (2027-2032) & (K Unit) Table 48. Global Prostacyclin Sales Market Share by Region (2027-2032) Table 49. Global Prostacyclin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Prostacyclin Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Prostacyclin Sales Value Share by Region (2021-2026) Table 52. Global Prostacyclin Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Prostacyclin Sales Value Share by Region (2027-2032) Table 54. Global Prostacyclin Market Average Price (USD/Unit) by Region (2021-2026) Table 55. Global Prostacyclin Market Average Price (USD/Unit) by Region (2027-2032) Table 56. Global Prostacyclin Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Table 57. Global Prostacyclin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Prostacyclin Sales by Country (2021-2026) & (K Unit) Table 59. Global Prostacyclin Sales Market Share by Country (2021-2026) Table 60. Global Prostacyclin Sales by Country (2027-2032) & (K Unit) Table 61. Global Prostacyclin Sales Market Share by Country (2027-2032) Table 62. Global Prostacyclin Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Prostacyclin Sales Value Market Share by Country (2021-2026) Table 64. Global Prostacyclin Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Prostacyclin Sales Value Market Share by Country (2027-2032) Table 66. United Therapeutics Company Information Table 67. United Therapeutics Business Overview Table 68. United Therapeutics Prostacyclin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 69. United Therapeutics Prostacyclin Product Portfolio Table 70. United Therapeutics Recent Development Table 71. Actelion (J & J) Company Information Table 72. Actelion (J & J) Business Overview Table 73. Actelion (J & J) Prostacyclin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 74. Actelion (J & J) Prostacyclin Product Portfolio Table 75. Actelion (J & J) Recent Development Table 76. GSK Company Information Table 77. GSK Business Overview Table 78. GSK Prostacyclin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 79. GSK Prostacyclin Product Portfolio Table 80. GSK Recent Development Table 81. Teva Company Information Table 82. Teva Business Overview Table 83. Teva Prostacyclin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 84. Teva Prostacyclin Product Portfolio Table 85. Teva Recent Development Table 86. Toray Company Information Table 87. Toray Business Overview Table 88. Toray Prostacyclin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 89. Toray Prostacyclin Product Portfolio Table 90. Toray Recent Development Table 91. Tide Pharma Company Information Table 92. Tide Pharma Business Overview Table 93. Tide Pharma Prostacyclin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. Tide Pharma Prostacyclin Product Portfolio Table 95. Tide Pharma Recent Development Table 96. Bayer AG Company Information Table 97. Bayer AG Business Overview Table 98. Bayer AG Prostacyclin Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Bayer AG Prostacyclin Product Portfolio Table 100. Bayer AG Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. Prostacyclin Distributors List Table 104. Prostacyclin Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Prostacyclin Product Image Figure 2. Global Prostacyclin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prostacyclin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Prostacyclin Sales (2021-2032) & (K Unit) Figure 5. Global Prostacyclin Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Prostacyclin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Epoprostenol Sodium Image Figure 10. Treprostinil Image Figure 11. Iloprost Image Figure 12. Beraprost Sodium Image Figure 13. Global Prostacyclin Sales Volume by Type (2021 VS 2025 VS 2032) & (K Unit) Figure 14. Global Prostacyclin Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Prostacyclin Sales Volume Share by Type (2021-2032) Figure 16. Global Prostacyclin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Prostacyclin Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Prostacyclin Sales Value Share by Type (2021-2032) Figure 19. For Injection Image Figure 20. For Oral Image Figure 21. For Inhalation Image Figure 22. Global Prostacyclin Sales Volume by Application (2021 VS 2025 VS 2032) & (K Unit) Figure 23. Global Prostacyclin Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Prostacyclin Sales Volume Share by Application (2021-2032) Figure 25. Global Prostacyclin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Prostacyclin Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Prostacyclin Sales Value Share by Application (2021-2032) Figure 28. Global Prostacyclin Sales by Region: 2021 VS 2025 VS 2032 (K Unit) Figure 29. Global Prostacyclin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Prostacyclin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Prostacyclin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Prostacyclin Sales Value (2021-2032) & (US$ Million) Figure 33. North America Prostacyclin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Prostacyclin Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Prostacyclin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Prostacyclin Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Prostacyclin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Prostacyclin Sales Value (2021-2032) & (US$ Million) Figure 39. South America Prostacyclin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Prostacyclin Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Prostacyclin Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Prostacyclin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Prostacyclin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Prostacyclin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Prostacyclin Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Prostacyclin Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Epoprostenol Sodium
  • Treprostinil
  • Iloprost
  • Beraprost Sodium
Applications
  • For Injection
  • For Oral
  • For Inhalation
Companies covered
  • United Therapeutics
  • Actelion (J & J)
  • GSK
  • Teva
  • Toray
  • Tide Pharma
  • Bayer AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Prostacyclin Sales Value (2021-2032)
  4. 1.2.2 Global Prostacyclin Sales Volume (2021-2032)
  5. 1.2.3 Global Prostacyclin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Prostacyclin Market Dynamics
  1. 2.1 Prostacyclin Industry Trends
  2. 2.2 Prostacyclin Industry Drivers
  3. 2.3 Prostacyclin Industry Opportunities and Challenges
  4. 2.4 Prostacyclin Industry Restraints
3 Prostacyclin Market by Company
  1. 3.1 Global Prostacyclin Company Revenue Ranking in 2025
  2. 3.2 Global Prostacyclin Revenue by Company (2021-2026)
  3. 3.3 Global Prostacyclin Sales Volume by Company (2021-2026)
  4. 3.4 Global Prostacyclin Average Price by Company (2021-2026)
  5. 3.5 Global Prostacyclin Company Ranking (2024-2026)
  6. 3.6 Global Prostacyclin Company Manufacturing Base and Headquarters
  7. 3.7 Global Prostacyclin Company Product Type and Application
  8. 3.8 Global Prostacyclin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Prostacyclin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Prostacyclin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Prostacyclin Market by Type
  1. 4.1 Prostacyclin Type Introduction
  2. 4.1.1 Epoprostenol Sodium
  3. 4.1.2 Treprostinil
  4. 4.1.3 Iloprost
  5. 4.1.4 Beraprost Sodium
  6. 4.2 Global Prostacyclin Sales Volume by Type
  7. 4.2.1 Global Prostacyclin Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Prostacyclin Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Prostacyclin Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Prostacyclin Sales Value by Type
  11. 4.3.1 Global Prostacyclin Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Prostacyclin Sales Value by Type (2021-2032)
  13. 4.3.3 Global Prostacyclin Sales Value Share by Type (2021-2032)
5 Prostacyclin Market by Application
  1. 5.1 Prostacyclin Application Introduction
  2. 5.1.1 For Injection
  3. 5.1.2 For Oral
  4. 5.1.3 For Inhalation
  5. 5.2 Global Prostacyclin Sales Volume by Application
  6. 5.2.1 Global Prostacyclin Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Prostacyclin Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Prostacyclin Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Prostacyclin Sales Value by Application
  10. 5.3.1 Global Prostacyclin Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Prostacyclin Sales Value by Application (2021-2032)
  12. 5.3.3 Global Prostacyclin Sales Value Share by Application (2021-2032)
6 Prostacyclin Regional Sales and Value Analysis
  1. 6.1 Global Prostacyclin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prostacyclin Sales by Region (2021-2032)
  3. 6.2.1 Global Prostacyclin Sales by Region: 2021-2026
  4. 6.2.2 Global Prostacyclin Sales by Region (2027-2032)
  5. 6.3 Global Prostacyclin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Prostacyclin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Prostacyclin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Prostacyclin Sales Value by Region (2027-2032)
  9. 6.5 Global Prostacyclin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Prostacyclin Sales Value (2021-2032)
  12. 6.6.2 North America Prostacyclin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Prostacyclin Sales Value (2021-2032)
  15. 6.7.2 Europe Prostacyclin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Prostacyclin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Prostacyclin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Prostacyclin Sales Value (2021-2032)
  21. 6.9.2 South America Prostacyclin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Prostacyclin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Prostacyclin Sales Value Share by Country, 2025 VS 2032
7 Prostacyclin Country-level Sales and Value Analysis
  1. 7.1 Global Prostacyclin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Prostacyclin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Prostacyclin Sales by Country (2021-2032)
  4. 7.3.1 Global Prostacyclin Sales by Country (2021-2026)
  5. 7.3.2 Global Prostacyclin Sales by Country (2027-2032)
  6. 7.4 Global Prostacyclin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Prostacyclin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Prostacyclin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Prostacyclin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Prostacyclin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Prostacyclin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Prostacyclin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Prostacyclin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Prostacyclin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Prostacyclin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Prostacyclin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Prostacyclin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Prostacyclin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Prostacyclin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Prostacyclin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Prostacyclin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Prostacyclin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Prostacyclin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Prostacyclin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Prostacyclin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Prostacyclin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Prostacyclin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Prostacyclin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Prostacyclin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Prostacyclin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Prostacyclin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Prostacyclin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Prostacyclin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Prostacyclin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Prostacyclin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Prostacyclin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Prostacyclin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Prostacyclin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Prostacyclin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Prostacyclin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Prostacyclin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Prostacyclin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Prostacyclin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Prostacyclin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Prostacyclin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Prostacyclin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Prostacyclin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Prostacyclin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Prostacyclin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Prostacyclin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Prostacyclin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Prostacyclin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Prostacyclin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Prostacyclin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Prostacyclin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Prostacyclin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Prostacyclin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Prostacyclin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Prostacyclin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Prostacyclin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Prostacyclin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Prostacyclin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Prostacyclin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Prostacyclin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Prostacyclin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Prostacyclin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Prostacyclin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Prostacyclin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Prostacyclin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Prostacyclin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Prostacyclin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Prostacyclin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Prostacyclin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Prostacyclin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Prostacyclin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Prostacyclin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Prostacyclin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Prostacyclin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Prostacyclin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Prostacyclin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Prostacyclin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Prostacyclin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Prostacyclin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Prostacyclin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Prostacyclin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Prostacyclin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Prostacyclin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Prostacyclin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Prostacyclin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Prostacyclin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Prostacyclin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Prostacyclin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 United Therapeutics
  2. 8.1.1 United Therapeutics Company Information
  3. 8.1.2 United Therapeutics Business Overview
  4. 8.1.3 United Therapeutics Prostacyclin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 United Therapeutics Prostacyclin Product Portfolio
  6. 8.1.5 United Therapeutics Recent Developments
  7. 8.2 Actelion (J & J)
  8. 8.2.1 Actelion (J & J) Company Information
  9. 8.2.2 Actelion (J & J) Business Overview
  10. 8.2.3 Actelion (J & J) Prostacyclin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Actelion (J & J) Prostacyclin Product Portfolio
  12. 8.2.5 Actelion (J & J) Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Prostacyclin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GSK Prostacyclin Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Teva
  20. 8.4.1 Teva Company Information
  21. 8.4.2 Teva Business Overview
  22. 8.4.3 Teva Prostacyclin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Teva Prostacyclin Product Portfolio
  24. 8.4.5 Teva Recent Developments
  25. 8.5 Toray
  26. 8.5.1 Toray Company Information
  27. 8.5.2 Toray Business Overview
  28. 8.5.3 Toray Prostacyclin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Toray Prostacyclin Product Portfolio
  30. 8.5.5 Toray Recent Developments
  31. 8.6 Tide Pharma
  32. 8.6.1 Tide Pharma Company Information
  33. 8.6.2 Tide Pharma Business Overview
  34. 8.6.3 Tide Pharma Prostacyclin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Tide Pharma Prostacyclin Product Portfolio
  36. 8.6.5 Tide Pharma Recent Developments
  37. 8.7 Bayer AG
  38. 8.7.1 Bayer AG Company Information
  39. 8.7.2 Bayer AG Business Overview
  40. 8.7.3 Bayer AG Prostacyclin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bayer AG Prostacyclin Product Portfolio
  42. 8.7.5 Bayer AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Prostacyclin Value Chain Analysis
  2. 9.1.1 Prostacyclin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Prostacyclin Sales Mode & Process
  6. 9.2 Prostacyclin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Prostacyclin Distributors
  9. 9.2.3 Prostacyclin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst